August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights

View Additional ASCO 2019 Coverage

ASCO 2019 Presidential Address: Removing Disparities in Cancer Care
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Disparities in Oncology
Read More
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Renal-Cell Carcinoma
Read More
Access to Health Insurance Reduces Disparities in Cancer Care: The Case for the ACA
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Disparities in Oncology
Read More
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer
Phoebe Starr
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - Prostate Cancer
Read More
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - FDA Approvals
Read More
Xpovio Receives FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - FDA Approvals
Read More
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - FDA Approvals
Read More
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - FDA Approvals
Read More
Keytruda Receives New Indication for Metastatic Small-Cell Lung Cancer After Disease Progression
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - FDA Approvals
Read More
Darzalex Combined with Revlimid and Dexamethasone New First-Line Regimen for Patients with Multiple Myeloma Ineligible for Transplant
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights - FDA Approvals
Read More
Page 1 of 3
Results 1 - 10 of 30
  • Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME